Article Text

Download PDFPDF
Case report
Primary small cell carcinoma of the urinary bladder
  1. Sumaira Qayoom1,
  2. Deep Chakrabarti2,
  3. Fatima Khan1 and
  4. Madhu Mati Goel1
  1. 1 Department of Pathology, King George’s Medical University, Lucknow, Uttar Pradesh, India
  2. 2 Department of Radiotherapy, King George’s Medical University, Lucknow, Uttar Pradesh, India
  1. Correspondence to Dr Deep Chakrabarti, deepchakrabarti.19{at}


Small cell carcinoma of the urinary bladder (SCCB) is an extremely rare but aggressive tumour constituting less than 0.7% of all urinary bladder tumours. It is often misdiagnosed as transitional cell carcinoma, owing to the similarities in presentation. Diagnosis of SCCB is based on the WHO criteria for small cell lung carcinoma. A 58-year-old man who had presented with haematuria and burning micturition for 3 months was initially diagnosed as high-grade muscle-invasive urothelial carcinoma based on the TURBT specimen. The patient was put on neoadjuvant chemotherapy, but presented again with haematuria and back pain after 3 months. Imaging studies showed a lesion in the posterolateral wall of the urinary bladder, along with partial collapse and anterior wedging of L1 vertebra. He underwent TURBT, and on the basis of histopathology and immunohistochemistry, a diagnosis of primary SCCB bladder with vertebral metastasis was made.

  • Pathology
  • Urological Cancer
  • Hematuria
  • Urological Surgery
  • Radiotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter deep190690

  • Contributors SQ conceived the case report, performed histopathology and IHC examination, and wrote the manuscript. DC was involved in patient treatment, image acquisition and helped in writing the manuscript. FK helped in image acquisition, and HPE and IHC reporting. MMG provided clinical oversight and expertise. All authors read and approved the final draft.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Next of kin consent obtained.